Wealthcare Advisory Partners LLC Reduces Holdings in Pfizer Inc. $PFE

Wealthcare Advisory Partners LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 12.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 147,571 shares of the biopharmaceutical company’s stock after selling 21,711 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Pfizer were worth $3,554,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PFE. First Bank & Trust grew its position in shares of Pfizer by 3.3% during the second quarter. First Bank & Trust now owns 265,755 shares of the biopharmaceutical company’s stock worth $6,399,000 after acquiring an additional 8,373 shares during the last quarter. Shrier Wealth Management LLC increased its holdings in shares of Pfizer by 1.8% in the 2nd quarter. Shrier Wealth Management LLC now owns 44,811 shares of the biopharmaceutical company’s stock valued at $1,079,000 after acquiring an additional 791 shares during the period. Revolve Wealth Partners LLC raised its position in Pfizer by 9.8% in the 2nd quarter. Revolve Wealth Partners LLC now owns 12,536 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 1,114 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its position in Pfizer by 7.9% in the 2nd quarter. Key Client Fiduciary Advisors LLC now owns 31,030 shares of the biopharmaceutical company’s stock valued at $747,000 after purchasing an additional 2,261 shares during the last quarter. Finally, World Equity Group Inc. boosted its stake in Pfizer by 5.3% during the 2nd quarter. World Equity Group Inc. now owns 16,025 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 810 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on PFE shares. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price objective for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Pfizer in a research note on Monday, August 3rd. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Raised 2026 outlook and cost savings: Pfizer increased its 2026 guidance after reporting second-quarter earnings of $0.77 per share versus the $0.68 consensus estimate and revenue of $15.03 billion versus $14.40 billion expected. Non-COVID products grew 5%, while management is targeting approximately $9.7 billion in savings, supporting profitability. Pfizer Q2 2026 Earnings Call Transcript
• Positive Sentiment: Pipeline offers a potential growth replacement: Investor coverage is highlighting Pfizer’s expanding non-COVID pipeline and strategic efforts to reduce its dependence on pandemic products. A successful pipeline could help offset upcoming revenue losses. Pfizer’s Pipeline Could Change Everything
• Neutral Sentiment: Income appeal remains significant: Pfizer’s roughly 6.4% dividend yield is well above the S&P 500 average, making PFE attractive to income-focused investors, although the high payout also reflects concerns about earnings quality and future growth. Pfizer vs AbbVie: What’s the Better Dividend Stock
• Negative Sentiment: Guidance increase may be less durable: Analysts noted that much of the improved 2026 outlook relies on a drug approaching patent expiry. That creates a potential revenue cliff from generic competition, though Pfizer says it is implementing measures to address the risk. Pfizer Raised 2026 Guidance
• Negative Sentiment: Dividend-cut concerns persist: Pfizer’s earnings have reportedly declined sharply this year, raising questions about whether its elevated dividend is sustainable if cash flow and earnings remain under pressure. Pfizer Earnings and Dividend Cut Concerns
• Negative Sentiment: Legal liability adds a financial overhang: Pfizer agreed to a $44 million settlement related to Chantix, creating a modest near-term cost and additional headline risk. Pfizer Chantix Settlement

Pfizer Stock Performance

Shares of PFE opened at $26.61 on Wednesday. The stock has a market capitalization of $151.67 billion, a P/E ratio of 35.01 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The company’s fifty day moving average is $25.07 and its two-hundred day moving average is $26.18.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.97 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.